Opthea Limited (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea Limited (ASX: OPT)
Latest News
Share Fallers
Why Cleanaway, Crown, Opthea, & Zoono shares are sinking lower today
Growth Shares
2 exciting ASX mid cap ASX growth shares to buy for the long term
⏸️ ASX Shares
2 exciting ASX healthcare shares to buy for the long term
Share Market News
Opthea share price bounces with Nasdaq listing on the cards
Share Gainers
Opthea share price surges higher on FDA news
⏸️ Investing
Why Opthea shares could offer big growth potential
Share Market News
Why the Opthea share price surged more than 20% today
Share Market News
Why these 9 ASX shares have doubled in value in the past year
Share Market News
Brokers name 3 ASX shares to buy right now
Healthcare Shares
Why the Opthea share price has skyrocketed 350% in the past year
⏸️ ASX Shares
EML Payments and these ASX mid cap shares could be destined for big things
Share Market News
3 ASX biotech shares that have soared higher today
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Opthea Limited
Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage.
